CQP 201‐403 in Parkinson's disease: An open‐label pilot study
Identifieur interne : 003907 ( Istex/Corpus ); précédent : 003906; suivant : 003908CQP 201‐403 in Parkinson's disease: An open‐label pilot study
Auteurs : Pfeiffer ; Leonel H. Herrera ; Carolyn S. Glaeske ; Ruth E. HofmanSource :
- Movement Disorders [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
Abstract
The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.
Url:
DOI: 10.1002/mds.870040310
Links to Exploration step
ISTEX:3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title><author><name sortKey="Pfeiffer" sort="Pfeiffer" uniqKey="Pfeiffer" last="Pfeiffer">Pfeiffer</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Herrera, Leonel H" sort="Herrera, Leonel H" uniqKey="Herrera L" first="Leonel H." last="Herrera">Leonel H. Herrera</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Glaeske, Carolyn S" sort="Glaeske, Carolyn S" uniqKey="Glaeske C" first="Carolyn S." last="Glaeske">Carolyn S. Glaeske</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hofman, Ruth E" sort="Hofman, Ruth E" uniqKey="Hofman R" first="Ruth E." last="Hofman">Ruth E. Hofman</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040310</idno><idno type="url">https://api.istex.fr/document/3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003907</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title><author><name sortKey="Pfeiffer" sort="Pfeiffer" uniqKey="Pfeiffer" last="Pfeiffer">Pfeiffer</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Herrera, Leonel H" sort="Herrera, Leonel H" uniqKey="Herrera L" first="Leonel H." last="Herrera">Leonel H. Herrera</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Glaeske, Carolyn S" sort="Glaeske, Carolyn S" uniqKey="Glaeske C" first="Carolyn S." last="Glaeske">Carolyn S. Glaeske</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hofman, Ruth E" sort="Hofman, Ruth E" uniqKey="Hofman R" first="Ruth E." last="Hofman">Ruth E. Hofman</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="278">278</biblScope><biblScope unit="page" to="281">281</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619</idno><idno type="DOI">10.1002/mds.870040310</idno><idno type="ArticleID">MDS870040310</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CQP 201‐403</term><term>Dopamine agonist</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Pfeiffer</name><affiliations><json:string>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>Leonel H. Herrera</name><affiliations><json:string>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>Carolyn S. Glaeske</name><affiliations><json:string>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>Ruth E. Hofman</name><affiliations><json:string>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CQP 201‐403</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.</abstract><qualityIndicators><score>2.451</score><pdfVersion>1.3</pdfVersion><pdfPageSize>486 x 720.24 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>543</abstractCharCount><pdfWordCount>1491</pdfWordCount><pdfCharCount>9379</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>80</abstractWordCount></qualityIndicators><title>CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title><genre><json:string>Serial article</json:string></genre><host><volume>4</volume><pages><total>4</total><last>281</last><first>278</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1002/mds.870040310</json:string></doi><id>3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title><author><persName><surname>Pfeiffer</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Section of Neurology, Department of Internal Medicine, University of Nebraska Medical Center, 42nd & Dewey Avenue, Omaha, NE 68105–1065, U.S.A</p></note><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">Leonel H.</forename><surname>Herrera</surname></persName><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">Carolyn S.</forename><surname>Glaeske</surname></persName><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">Ruth E.</forename><surname>Hofman</surname></persName><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989"></date><biblScope unit="vol">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="278">278</biblScope><biblScope unit="page" to="281">281</biblScope></imprint></monogr><idno type="istex">3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619</idno><idno type="DOI">10.1002/mds.870040310</idno><idno type="ArticleID">MDS870040310</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Dopamine agonist</term></item><item><term>CQP 201‐403</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v4:3</doi><numberingGroup><numbering type="journalVolume" number="4">4</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1989">1989</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870040310</doi><idGroup><id type="unit" value="MDS870040310"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 1989 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">278</numbering><numbering type="pageLast">281</numbering></numberingGroup><correspondenceTo>Section of Neurology, Department of Internal Medicine, University of Nebraska Medical Center, 42nd & Dewey Avenue, Omaha, NE 68105–1065, U.S.A</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870040310.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="4"></count></countGroup><titleGroup><title type="main" xml:lang="en">CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title><title type="short" xml:lang="en">CQP 201‐403 IN PARKINSON'S DISEASE</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Ronald F.</givenNames><familyName>Pfeiffer</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Leonel H.</givenNames><familyName>Herrera</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Carolyn S.</givenNames><familyName>Glaeske</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ruth E.</givenNames><familyName>Hofman</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">Dopamine agonist</keyword><keyword xml:id="kwd3">CQP 201‐403</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CQP 201‐403 IN PARKINSON'S DISEASE</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>CQP 201‐403 in Parkinson's disease: An open‐label pilot study</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Pfeiffer</namePart><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><description>Correspondence: Section of Neurology, Department of Internal Medicine, University of Nebraska Medical Center, 42nd & Dewey Avenue, Omaha, NE 68105–1065, U.S.A</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Leonel H.</namePart><namePart type="family">Herrera</namePart><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carolyn S.</namePart><namePart type="family">Glaeske</namePart><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ruth E.</namePart><namePart type="family">Hofman</namePart><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1989</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">4</extent></physicalDescription><abstract lang="en">The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Dopamine agonist</topic><topic>CQP 201‐403</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>278</start><end>281</end><total>4</total></extent></part></relatedItem><identifier type="istex">3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619</identifier><identifier type="DOI">10.1002/mds.870040310</identifier><identifier type="ArticleID">MDS870040310</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1989 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003907 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003907 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3DC8C94CCCD96953F9CDA05F8B9F9C29B934D619
|texte= CQP 201‐403 in Parkinson's disease: An open‐label pilot study
}}
| This area was generated with Dilib version V0.6.23. |  |